Idiopathic Thrombocytopenic Purpura (ITP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Idiopathic Thrombocytopenic Purpura (ITP) is a condition characterized by a low platelet count in the blood, with no known cause. This condition is also called Immune Thrombocytopenic Purpura, which is believed to be related to antibodies against platelets. The normal platelet count in adults is between 150,000 to 450,000/mm3. A low platelet count below 50,000/mm3 increases the risk of bleeding from trauma, while counts below 20,000/mm3 increase the risk of spontaneous bleeding. ITP can be acute or chronic. Acute ITP is the most common form of the disorder and is commonly seen in young children, typically between the ages of 2 to 6 years. It usually follows a viral illness, and symptoms disappear within a few weeks. Chronic ITP, on the other hand, can occur at any age, and symptoms can last for several years. Females are more likely to contract this form of the disease, and it can often recur. The acute form of ITP may be caused by drug exposure or infection. In contrast, the chronic form is an autoimmune disorder that can be associated with chronic lymphatic leukemia and other disorders. Extremely low platelet counts (less than 10,000 to 20,000/mm3) increase the risk of significant bleeding, including intracranial hemorrhage. The management of acute ITP typically involves intravenous immunoglobulins (IVIG) and corticosteroids. Chronic ITP management includes steroids, IVIG, androgens, antiRh(D), recombinant human interferon-alpha-2b, and immunosuppressive agents used alone or in combination.
·
The incidence of childhood ITP is estimated to
be 2.2 to 5.3 per 100,000 annually.
Thelansis’s “Idiopathic Thrombocytopenic
Purpura (ITP) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Idiopathic
Thrombocytopenic Purpura (ITP) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Idiopathic Thrombocytopenic Purpura (ITP) across 8 MM market from the centre
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Idiopathic Thrombocytopenic Purpura
(ITP) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment